Replies to post #6607 on Arbutus Biopharma Corporation (ABUS)

[DewDiligence]

ABUS’ AB-836 HBV capsid inhibitor shows_safety_signal_in_phase-1b_trial—see slide #18 from today’s EASL CC:

https://investor.arbutusbio.com/static-files/a51bd38d-cd8a-4001-8077-6d0c842359b9:

As a result of the safety signal, ABUS will rerun a phase-1a trial (i.e. retest healthy volunteers) to gain further insight on the relevance of the signal.